Panaceum Spółka z Ograniczoną Odpowiedzialnością (KRS 0000069795, NIP 8561677112) is a Polish company, headquartered in Łódź, Łódzkie voivodeship. PANACEUM operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since December 6, 2001.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Panaceum
Identity
- Name
- Panaceum Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 6, 2001
- Registry status as of
- June 14, 2026
- Latest entry
- June 14, 2026
- Founding act
- 25.10.2001 R., NOTARIUSZ MARIUSZ CHMIELEWSKI, KANCELARIA NOTARIALNA W SZCZECINIE, REPERTORIUM A NR 15282/2001
Articles of association history (2)
- October 25, 2001: 25.10.2001 R., NOTARIUSZ MARIUSZ CHMIELEWSKI, KANCELARIA NOTARIALNA W SZCZECINIE, REPERTORIUM A NR 15282/2001
- October 11, 2023: 11.10.2023 R., REP. A NR 6636/2023, NOTARIUSZ BARTŁOMIEJ JANICKI, KANCELARIA NOTARIALNA W ALEKSANDROWIE ŁÓDZKIM, ZMIENIONO UMOWĘ W TEN SPOSÓB, ŻE NADANO CAŁEJ UMOWIE NOWE BRZMIENIE (PAR. 1-27)
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
Address and contact
- Address
- UL. KINGA C. GILLETTE, 11, 94-406, ŁÓDŹ, POLSKA
- Voivodeship
- ŁÓDZKIE
- District
- ŁÓDŹ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-91168-37036-WABRD-27
Risk and payment profile - Panaceum
Credibility rating
22 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
28
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
4
4/25 yrs
Board changes
4
4/25 yrs
PKD changes
3
3/25 yrs
Name changes
0
0/25 yrs
Data from 25 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Panaceum
Founded
December 6, 2001
24 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ŁÓDŹ
ŁÓDZKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
50.0 K PLN
Shareholders
2
shareholders
Board
3 people
Filed years
1 year
2018 · profitable: 0/1
Registry entries
49
latest: June 14, 2026
Risk signals
Revenue
N/A
2018
Net profit
-3.2 K PLN
2018
Assets
5.7 K PLN
2018
Equity
1.8 K PLN
2018
EBITDA
N/A
2018
no depreciation data
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Panaceum.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
